Protein carbamylation is associated with heart failure and mortality in diabetic patients with end-stage renal disease

Kidney International

Volumn 87, Issue 6, 2015, Pages 1201-1208

  Drechsler, Christiane ^a   Kalim, Sahir ^b   Wenger, Julia B ^b   Suntharalingam, Pirianthini ^c   Hod, Tammy ^d,e   Thadhani, Ravi I ^b   Karumanchi, S Ananth ^d,e   Wanner, Christoph ^a   Berg, Anders H ^c  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

cardiovascular disease; congestive heart failure; hemodialysis; urea; uremia; uremic toxins

Indexed keywords

ALBUMIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATORVASTATIN; PLACEBO; TROPONIN T; BRAIN NATRIURETIC PEPTIDE; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); SERUM ALBUMIN;

ADULT; AGED; ARTICLE; CARBAMOYLATION; CARDIOMYOPATHY; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; END STAGE RENAL DISEASE; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEART INJURY; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SUDDEN CARDIAC DEATH; SURVIVAL; VERY ELDERLY; ADVERSE EFFECTS; ATRIAL FIBRILLATION; BLOOD; CAUSE OF DEATH; COMORBIDITY; DEATH, SUDDEN, CARDIAC; DIABETIC NEPHROPATHIES; HYPERTENSION; KIDNEY FAILURE, CHRONIC; METABOLISM; MIDDLE AGED; MORTALITY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; UREMIA;

AGED; ATORVASTATIN CALCIUM; ATRIAL FIBRILLATION; CAUSE OF DEATH; CHOLESTEROL; COMORBIDITY; DEATH, SUDDEN, CARDIAC; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; RENAL DIALYSIS; RISK FACTORS; SERUM ALBUMIN; SURVIVAL RATE; TROPONIN T; UREMIA;

EID: 84930273894     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.429     Document Type: Article

References (35)

1. Stark GR. Reactions of cyanate with functional groups of proteins. 3. Reactions with amino and carboxyl groups. Biochemistry 1965; 4: 1030-1036.
2. Kraus LM, Kraus AP Jr. Carbamoylation of amino acids and proteins in uremia. Kidney Int Suppl 2001; 78: S102-S107.
3. Kalim S, Karumanchi SA, Thadhani RI et al. Protein carbamylation in kidney disease: pathogenesis and clinical implications. Am J Kidney Dis 2014; 64: 793-803.
4. Koeth RA, Kalantar-Zadeh K, Wang Z et al. Protein carbamylation predicts mortality in ESRD. J Am Soc Nephrol 2013; 24: 853-861.
5. Berg AH, Drechsler C, Wenger J et al. Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med 2013; 5: 175ra129.
6. Duranton F, Lundin U, Gayrard N et al. Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function. Clin J Am Soc Nephrol 2013; 9: 37-45.
7. Apostolov EO, Ray D, Savenka AV et al. Chronic uremia stimulates LDL carbamylation and atherosclerosis. Clin J Am Soc Nephrol 2010; 21: 1852-1857.
8. Apostolov EO, Shah SV, Ok E et al. Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin Chem 2005; 51: 719-728.
9. Ok E, Basnakian AG, Apostolov EO et al. Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease. Kidney Int 2005; 68: 173-178.
10. Apostolov EO, Shah SV, Ok E et al. Carbamylated low-density lipoprotein induces monocyte adhesion to endothelial cells through intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol 2007; 27: 826-832.
11. Apostolov EO, Shah SV, Ray D et al. Scavenger receptors of endothelial cells mediate the uptake and cellular proatherogenic effects of carbamylated LDL. Arterioscler Thromb Vasc Biol 2009; 29: 1622-1630.
12. Holzer M, Gauster M, Pfeifer T et al. Protein carbamylation renders highdensity lipoprotein dysfunctional. Antioxid Redox Signal 2011; 14: 2337-2346.
13. Holzer M, Zangger K, El-Gamal D et al. Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional highdensity lipoprotein. Antioxid Redox Signal 2012; 17: 1043-1052.
14. Wang Z, Nicholls SJ, Rodriguez ER et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007; 13: 1176-1184.
15. Green D, Roberts PR, New DI et al. Sudden cardiac death in hemodialysis patients: an in-depth review. Am J Kidney Dis 2011; 57: 921-929.
16. Rocco MV, Yan G, Gassman J et al. Comparison of causes of death using HEMO Study and HCFA end-stage renal disease death notification classification systems. The National Institutes of Health-funded Hemodialysis. Health Care Financing Administration. Am J Kidney Dis 2002; 39: 146-153.
17. Buzello M, Tornig J, Faulhaber J et al. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. Clin J Am Soc Nephrol 2003; 14: 311-316.
18. Lindner A, Charra B, Sherrard DJ et al. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 1974; 290: 697-701.
19. Lemos MM, Watanabe R, Carvalho AB et al. Effect of rosuvastatin and sevelamer on the progression of coronary artery calcification in chronic kidney disease: a pilot study. Clin Nephrol 2013; 80: 1-8.
20. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.
21. Fellstrom BC, Jardine AG, Schmieder RE et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 2009; 360: 1395-1407.
22. Karumanchi SA, Thadhani R. Kidney complications: why don?t statins always work? Nat Med 2010; 16: 38-40.
23. Duranton F, Depner TA, Argiles A. The saga of two centuries of urea: nontoxic toxin or vice versa? Semin Nephrol 2014; 34: 87-96.
24. Massy ZA. The role of lipids and uremic toxins in cardiovascular disease in CKD. Clin Exp Nephrol 2014; 18: 255-256.
25. Alhaj E, Alhaj N, Rahman I et al. Uremic cardiomyopathy: an underdiagnosed disease. Congest Heart Fail 2013; 19: E40-E45.
26. Chan CT, Floras JS, Miller JA et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002; 61: 2235-2239.
27. Pauly RP, Chan CT. Reversing the risk factor paradox: is daily nocturnal hemodialysis the solution? Semin Dial 2007; 20: 539-543.
28. Thomson BK, Huang SH, Chan C et al. Nocturnal home hemodialysis associates with improvement of electrocardiographic features linked to sudden cardiac death. ASAIO J 2013; 60: 99-105.
29. Kalantar-Zadeh K, Block G, Humphreys MH et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003; 63: 793-808.
30. Liu Y, Coresh J, Eustace JA et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA 2004; 291: 451-459.
31. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482.
32. Wanner C, Tonelli M. Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int 2014; 85: 1303-1309.
33. Shiu SW, Xiao SM, Wong Y et al. Carbamylation of LDL and its relationship with myeloperoxidase in type 2 diabetes mellitus. Clin Sci 2013; 126: 175-181.
34. Wanner C, Krane V, Marz W et al. Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics. Kidney Blood Press Res 2004; 27: 259-266.
35. Wanner C, Krane V, Marz W et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005; 353: 238-248.